Organization	Reference	URL
AHRQ	CHI (consolidated health informatics)	https://ushik.ahrq.gov/ViewItemDetails?&system=mdr&itemKey=74237000
AI Multiple	The Ultimate Guide to Synthetic Data in 2020, August 29, 2020	https://research.aimultiple.com/synthetic-data/
AMA	AMA Manual of Style	http://www.amamanualofstyle.com/
Applied Clinical Trials	Estimand Framework: What it is and Why You Need it. Applied Clinical Trials. February 27, 2020	https://www.appliedclinicaltrialsonline.com/view/estimand-framework-what-it-and-why-you-need-it
Australian Bureau of Statistics	Statistical Language - What are Variables?, Australian Bureau of Statistics, October 2013	https://www.abs.gov.au/websitedbs/a3121120.nsf/home/statistical+language+-+what+are+variables#:~:text=A%20variable%20is%20any%20characteristics,be%20called%20a%20data%20item.&text=It%20is%20called%20a%20variable,change%20in%20value%20over%20time.
Australian National Data Service	Working with Data, Australian National Data Service, Accessed 9/4/2020	https://www.ands.org.au/working-with-data/data-management/data-capture
Biomchem Med	McHugh ML. Power analysis in research. Biochem Med (Zagreb). 2008;18:263-274	
BMJ	British Medical Journal, Epidemiology for the uninitiated	https://www.bmj.com/about-bmj/resources-readers/publications/epidemiology-uninitiated/8-case-control-and-cross-sectional
BMJ	British Medical Journal, Epidemiology for the uninitiated, Chapter 8, Fifth Edition, BMJ Book 2004	https://www.bmj.com/about-bmj/resources-readers/publications/epidemiology-uninitiated/8-case-control-and-cross-sectional
CDC	What is Health Literacy? Oct 23, 2019	https://www.cdc.gov/healthliteracy/learn/index.html
CDC	Principles of Epidemiology in Public Health Practice, Third Edition. An Introduction to Applied Epidemiology and Biostatistics, Lesson 3: Measures of Risk, CDC 2012	https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section2.html#:~:text=Section%202%3A%20Morbidity%20Frequency%20Measures&text=Measures%20of%20morbidity%20frequency%20characterize,a%20given%20time%20(prevalence
CDC	Principles of Epidemiology in Public Health Practice, Third Edition. An Introduction to Applied Epidemiology and Biostatistics, Glossary, CDC 2014	https://www.cdc.gov/csels/dsepd/ss1978/glossary.html
CDC	How Flu Vaccine Effectiveness and Efficacy are Measured, Questions & Answers, CDC January 29, 2016	https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm
CDC	Principles of Epidemiology in Public Health Practice, Third Edition, An Introduction to Applied Epidemiology and Biostatistics, Oct 2006, Updated May 2012, US DHHS	https://stacks.cdc.gov/pdfjs/web/viewer.html?file=https://stacks.cdc.gov/view/cdc/6914/cdc_6914_DS1.pdf
CDISC	Clinical Data Interchange Standards Consortium	http://www.cdisc.org/
CIOMS	Glossary of ICH Terms and Definitions	https://cioms.ch/publications/product/glossary-of-ich-terms-and-definitions/
Clinical Research Manual: Practical Tools and Templates for Managing Clinical Research	Clinical Research Manual: Practical Tools and Templates for Managing Clinical Research Cavalieri Jennifer and Rupp Mark Clinical Research Manual: Practical Tools and Templates for Managing Clinical Research 336pp US$44.95 Sigma Theta Tau 9781937554637 1937554635 [Formula: see text]. Nurs Manag (Harrow). 2014 Aug 28;21(5):13.	https://pubmed.ncbi.nlm.nih.gov/25167109/
CONSORT	CONSORT Statement	http://www.consort-statement.org/consort-2010
CTTI (Clinical Trials Transformation Initiative)	CTTI Recommendations: Decentralized Clinical Trials, September 2018	https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/dct_recommendations_final.pdf
Deep AI	DeepAI Definitions	https://deepai.org/definitions
Deep AI	DeepAI Machine Learning Glossary and Terms	https://deepai.org/machine-learning-glossary-and-terms/deep-learning
Department of Health and Social Care, UK	Prevention is better than the cure: Our vision to help you live well for longer. Department of Health and Social Care, UK. 05 November 2018	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/753688/Prevention_is_better_than_cure_5-11.pdf
EDQM	EDQM Standard Terms controlled vocabularies for pharmaceutical dose forms Version 1.2.0 2019. Internal controlled vocabularies for pharmaceutical dose forms. Version 1.2.0 - 28 January 2019.	https://www.edqm.eu/en/d/513701
EMA	External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use	https://www.ema.europa.eu/human-regulatory/marketing-authorisation/clinical-data-publication/support-industry/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data
EMA	Guideline on good pharmacovigilance practices (GVP)	http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf
EMA	Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017	https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/2017_06_28_recommendation_on_axmps.pdf
EMA	Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials [EMA/INS/GCP/454280/2010]	https://www.ema.europa.eu/documents/regulatory-procedural-guideline/reflection-paper-expectations-electronic-source-data-data-transcribed-electronic-data-collection_en.pdf

EMA	Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007.	https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF
EMA	ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998	https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf
EMA	EMA Glossary of regulatory terms	https://www.ema.europa.eu/en/about-us/about-website/glossary
EMA	EMA NOTE FOR GUIDANCE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS, September 1998	https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf
EMA	EMA Glossary of regulatory terms	https://www.ema.europa.eu/en/about-us/about-website/glossary
EMA	EMA Glossary of Regulatory terms	https://www.ema.europa.eu/en/glossary/label-use#:~:text=Off-label%20use%20%7C%20European%20Medicines%20Agency%20Home%20Glossary,unapproved%20age%20group%2C%20dosage%2C%20or%20route%20of%20administration.
EU	Directive 95/46/EC	https://publications.europa.eu/en/publication-detail/-/publication/335ef9fc-250a-4dfa-a76d-5583b689e91e/language-en/format-PDF/source-79725998
EU	Regulation (EU) 2017/745	https://publications.europa.eu/en/publication-detail/-/publication/83bdc18f-315d-11e7-9412-01aa75ed71a1/language-en/format-PDF/source-58036705
EU	Regulation EU No 536/2014 [EU CTR]	https://ec.europa.eu/health/human-use/clinical-trials/regulation_en
EU	REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC	https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf
EU	EU GDPR	https://gdpr.eu/
EU EMA	Guideline on computerised systems and electronic data in clinical trials (europa.eu) EMA/INS/GCP/112288/2023	https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf?bcs-agent-scanner=76bbac43-e79c-254f-8ce8-685e2f03aed5
EUPATI	EUPATI Toolbox: Within-trial decisions: Unblinding and termination. 2023	https://toolbox.eupati.eu/resources/within-trial-decisions-unblinding-and-termination/#:~:text=Unblinding%20(Code%2Dbreaking),-What%20is%20unblinding&text=Unblinding%20occurs%20when%20that%20'blind,treatment%20the%20participant%20is%20receiving
FDA	21 CFR 210.3	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3
FDA	21 CFR 3.2 (e) FAQ	https://www.fda.gov/combination-products/about-combination-products/frequently-asked-questions-about-combination-products
FDA	21 CFR 310.305	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310.305
FDA	21 CFR 312.42	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.42
FDA	21 CFR 803.3	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=803.3
FDA	21 CFR 820.20	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=820.20
FDA	21 CFR Part 11	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11
FDA	Acronyms and Abbreviations	https://www.accessdata.fda.gov/scripts/cder/acronyms/index.cfm
FDA	Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry, FDA Nov 2019	https://www.fda.gov/media/78495/download
FDA	Biologics Guidances	http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
FDA	Collection of Race and Ethnicity Data in Clinical Trials, Guidance for Industry and Food and Drug Administration Staff, Document issued on October 26, 2016	https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126396.pdf
FDA	Electronic Submission File Formats and Specifications. Orientation and Best Practices For Data Formats and Submission To The Center For Tobacco Products. January 2018	https://www.fda.gov/media/110979/download
FDA	Emergency Use Authorization of Medical Products and Related Authorities. FDA Guidance for Industry and Other Stakeholders. January 2017.	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities
FDA	Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions, April 2015	https://www.govinfo.gov/content/pkg/FR-2015-04-13/pdf/2015-08364.pdf
FDA	FDA Biological Product Definitions	https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf
FDA	FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards March 2020 Updated on July 2, 2020	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency

FDA	FDA Guidance on Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry, July 2018	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry
FDA	Finding and Learning about Side Effects (adverse reactions), July 2018	https://www.fda.gov/drugs/drug-information-consumers/finding-and-learning-about-side-effects-adverse-reactions
FDA	Framework for FDA's Real World Evidence Program. December 2018	https://www.fda.gov/media/120060/download#targetText=FDA's%20RWE%20Program%20provides%20an,and%20strategies%20to%20address%20them.
FDA	General Principles of Software Validation; Final Guidance for Industry and FDA Staff	https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085371.pdf
FDA	Glossary of Terms	http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm
FDA	Glossary Of Terms On Clinical Trials For Patient Engagement Advisory Committee Meeting	https://www.fda.gov/media/108378/download#:~:text=Enrollment,of%20answering%20the%20trial%20questions
FDA	Guidance for Industry Adaptive Designs for Clinical Trials of Drugs and Biologics, November 2019	https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf
FDA	Guidance for Industry and Food and Drug Administration Staff Applying Human Factors and Usability Engineering to Medical Devices, February 2016	https://wayback.archive-it.org/7993/20190911173106/https://www.fda.gov/medical-devices/workshops-conferences-medical-devices/applying-human-factors-and-usability-engineering-medical-devices-february-19-2016
FDA	Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies	https://www.fda.gov/media/79394/download
FDA	Guidance for Industry Computerized Systems Used in Clinical Investigations, May 2007	https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070266.pdf
FDA	Guidance for Industry Electronic Source Data in Clinical Investigations, September 2013	https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm328691.pdf
FDA	Guidance for Industry Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications, May 2003	https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf
FDA	Guidance for Industry Part 11, Electronic Records; Electronic Signatures - Scope and Application, August 2003	http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125125.pdf
FDA	Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, December 2009	http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
FDA	Guidance for Industry Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product, May 2019	https://www.fda.gov/media/135612/download
FDA	Guidance for Industry, Use of Electronic Health Record Data in Clinical Investigations, July 2018	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry
FDA	Master Protocols: Efficient Clinical Trial Design Strategies To Expedite Development of Oncology Drugs and Biologics. Guidance for Industry. October 2018	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and
FDA	Medical Device Development Tools (MDDT)	https://www.fda.gov/MedicalDevices/ScienceandResearch/MedicalDeviceDevelopmentToolsMDDT/default.htm
FDA	Multiple Endpoints inClinical Trials, Draft Guidance for Industry, January 2017	https://www.fda.gov/media/102657/download
FDA	Patient-Focused Drug Development Glossary	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm610317.htm
FDA	Plain Writing Act of 2010, FDA	https://www.fda.gov/media/84926/download; https://www.fda.gov/about-fda/plain-writing-its-law/federal-plain-language-guidelines
FDA	Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry. January 2019	https://www.fda.gov/media/120094/download
FDA	Reviewer Guidance Evaluating the Risks of Drug Exposure in Human Pregnancies, April 2005	https://www.fda.gov/downloads/Drugs/Guidances/ucm071645.pdf
FDA	Science & Research	http://wayback.archive-it.org/7993/20180907200008/https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf
FDA	Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research Guidance for Industry. March 2019	https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm589416.pdf?utm_campaign=Recently%20Posted%20Guidance%20Documents%203%2F29%2F2019&utm_medium=email&utm_source=Eloqua
FDA	Study Data Standards Resources	https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources
FDA	Study Data Technical Conformance Guide, Technical Specifications Document, March 2019	https://www.fda.gov/media/122913/download
FDA	Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Guidance for Industry and Food and Drug Administration Staff. August 2017	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices

FDA	Long Term Follow-up After Administration of Human Gene Therapy Products. FDA Guidance for Industry. JANUARY 2020	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products
FDA	Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. FDA GUIDANCE DOCUMENT. MAY 1998	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-clinical-evidence-effectiveness-human-drug-and-biological-products
FDA	Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. FDA Guidance for Industry (DRAFT GUIDANCE). December 2019	https://www.fda.gov/media/133660/download
FDA	Non-Inferiority Clinical Trials to Establish Effectiveness. FDA Guidance for Industry. November 2016	https://www.fda.gov/media/78504/download
FDA	FDA Guidance for industry end of Phase 2a meetings, September 2009	https://www.fda.gov/media/72211/download
FDA	21 CRF Part 312.21 Phases of an investigation	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21&SearchTerm=Phase
FDA	Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Draft Guidance for Industry. December 2019	https://www.fda.gov/media/133660/download
FDA	GUIDANCE DOCUMENT, E9 Statistical Principles for Clinical Trials, SEPTEMBER 1998	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9-statistical-principles-clinical-trials; https://www.fda.gov/media/71336/download
FDA	FDA Draft Guidance, Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products Guidance for Industry, November 2018	https://www.fda.gov/media/117976/download
FDA	FDA Webpage Postmarketing Requirements and Commitments: Introduction, 01/12/2016	https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments
FDA	FDA Draft Guidance, Data Standards for Drug and Biological Product Submissions Containing Real-World Data, OCTOBER 2021	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data
FDA	BEST Resource	https://www.fda.gov/drugs/development-resources/best-resource-taxonomy; https://www.ncbi.nlm.nih.gov/books/NBK338448/; https://www.fda.gov/drugs/development-resources/best-resource-taxonomy
FDA	FDA Guidance: Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. March 2022	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics
FDA	45 CFR 63.32	https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-63/subpart-C/section-63.32
FDA	FDA Glossary of Terms	https://www.fda.gov/patients/clinical-trials-what-patients-need-know/glossary-terms#D-1
FDA	FDA GLOSSARY OF TERMS ON CLINICAL TRIALS FOR PATIENT ENGAGEMENT ADVISORY COMMITTEE MEETING	https://www.fda.gov/media/108378/download
FDA	What is Gene Therapy?, US FDA, 07/25/2018	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
FDA	FDA Best Practices in Developing Proprietary Names for Human Prescription Drug Products, Guidance for Industry, December 2020	https://www.fda.gov/media/88496/download
FDA	US FDA, 21 CFR 299.4	https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-299/subpart-A/section-299.4
FDA	After US FDA, Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry, 2022	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and
HHS	HIPAA	https://www.hhs.gov/hipaa/index.html
HHS	Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues, September 21, 2010	https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/subjectwithdrawal.pdf
HL7	Glossary of Terms	https://www.hl7.org/documentcenter/public/calendarofevents/FirstTime/Glossary%20of%20terms.pdf
HL7	Structured Product Labeling (SPL)	http://www.hl7.org/implement/standards/product_brief.cfm?product_id=96
HMA	Medicines Approval system	http://www.hma.eu/medicinesapprovalsystem.html
HyperStat	Online Glossary	http://davidmlane.com/hyperstat/glossary.html
ICH	Efficacy Guidelines	https://www.ich.org/page/efficacy-guidelines
ICH	ICH E9 R1 Addendum	https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf
ICH	ICH E6(R2) Glossary	https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101734075-pdf
IMDRF	"Software as a Medical Device": Possible Framework for Risk Categorization and Corresponding Considerations Authoring Group: IMDRF Software as a Medical Device (SaMD) Working Group Date: 18 September 2014	http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf

IMI	IMI-GetReal Glossary Workgroup, 2016 GetReal - Project No. 115546, WP1: Deliverable D1.3	https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf
Institute for Work and Health	Primary, Secondary, and Tertiary Prevention, Institute for Work and Health, Published: April 2015	https://www.iwh.on.ca/what-researchers-mean-by/primary-secondary-and-tertiary-prevention
International Committee of Medical Journal Editors	ICMJE Recommendations	https://icmje.org/recommendations/
IOM	National Academies of Sciences, Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: National Academies Press, 2015, accessed 2022-09-0	https://nap.nationalacademies.org/catalog/18998/sharing-clinical-trial-data-maximizing-benefits-minimizing-risk
ISO	Health informatics -- Pseudonymization	https://www.iso.org/standard/63553.html
ISO	ISO 11238 2018-07 Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated information on substances	https://www.iso.org/standard/69697.html
ISO	ISO 11615 2017-10 Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated medicinal product information	https://www.iso.org/standard/70150.html
ISO	Software engineering -- Guidelines for the application of ISO 9001:2000 to computer software	https://www.iso.org/standard/35867.html
Kaplan, A; Haenlein, M (1 January 2019) Business Horizons	Kaplan, Andreas; Haenlein, Michael (1 January 2019). "Siri, Siri, in my hand: Who's the fairest in the land? On the interpretations, illustrations, and implications of artificial intelligence". Business Horizons. 62 (1): 15–25.	https://www.sciencedirect.com/science/article/pii/S0007681318301393?via%3Dihub
MedDRA	Medical Dictionary for Regulatory Activities	https://www.meddra.org/
MHRA	Guidance: Medical device stand-alone software including apps	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/717865/Software_flow_chart_Ed_1-05.pdf
MHRA	GxP Data Integrity Guidance and Definitions, March 2018	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/687246/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf
MSD Manual	Drug Interactions, By Shalini S. Lynch, PharmD, University of California San Francisco School of Pharmacy, Reviewed/Revised Jul 2022	https://www.msdmanuals.com/professional/clinical-pharmacology/factors-affecting-response-to-drugs/drug-interactions
Multiple	Goldoni and Johnson, 2007; Ciraci et al 2014	
n/a	D.L. Patrick, “Patient-Reported Outcomes (PROs): An Organizing Tool for Concepts, Measures, and Applications,” MAPI Quality of Life News Letter, 31, 1–5 (2003).	https://www.researchgate.net/publication/228734069_Patient-reported_outcomes_PROs_An_organizing_tool_for_concepts_measures_and_applications
n/a	Finkel, R, Clark, M. A., Champe, P. C. & Cubeddu, L. X. (eds) Lippincott's Illustrated Reviews: Pharmacology 4th edn (Lippincott Williams & Wilkins, 2008).	n/a
n/a	Glossary for Healthcare Standards, W.E. Hammond, 1995	n/a
n/a	L. Huber, “In Search of Standard Definitions for Validation, Qualification, Verification and Calibration,” BioPharm, 12 (4) 56–58 (1999).	n/a
n/a	M.L. Schuyl and T. Engel, “A Review of the Source Document Verification Process in Clinical Trials,” DIA Journal, 33, 789–797 (1999).	https://journals.sagepub.com/doi/abs/10.1177/009286159502900431?journalCode=dijb
n/a	Rubio DM, Schoenbaum EE, Lee LS, Schteingart DE, Marantz PR, Anderson KE, Platt LD, Baez A, Esposito K. Defining translational research: implications for training. Acad Med. 2010 Mar;85(3):470-5.	https://www.ncbi.nlm.nih.gov/pubmed/20182120
n/a	Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010 Dec;126(6):2234-42.	https://www.ncbi.nlm.nih.gov/pubmed/20697313
n/a	Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70.	https://www.ncbi.nlm.nih.gov/pubmed/28679092
National Databases of Indian Medical Journals	R. Khosla, D.D. Verma, A. Kapur et al.,“Efficient Source Data Verification,” Indian J. Pharm, 32, 180–186 (2000).	https://doi.org/10.1016/j.cct.2016.09.003
NCBI	Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M; PRO Harmonization Group. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003 Sep-Oct;6(5):522-31.	https://www.ncbi.nlm.nih.gov/pubmed/14627058
NCBI	Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001 Apr 17;134(8):663-94.	https://www.ncbi.nlm.nih.gov/pubmed/11304107
NCBI	Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95.	https://www.ncbi.nlm.nih.gov/pubmed/11240971
NCBI	G.H. Guyatt, D.H. Feeney, D.L. Patrick, “Measuring Health-Related Quality of Life,” Ann Intern Med., 118, 622–629 (1993).	https://www.ncbi.nlm.nih.gov/pubmed/8452328

NCBI	NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource	https://www.ncbi.nlm.nih.gov/books/NBK338448/
NCI	NCI Thesaurus	https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=19.11d&ns=ncit&code=C103180&key=1599980774&b=1&n=null
NCI	NCI's Dictionary of Cancer Terms	https://www.cancer.gov/publications/dictionaries/cancer-terms
NCI-EVS	NCI	https://evsexplore.semantics.cancer.gov/evsexplore/welcome
NHS	What are side effects?, August 2018	https://www.nhs.uk/common-health-questions/medicines/what-are-side-effects/
NIH	ClinicalTrials.gov	https://clinicaltrials.gov/
NIH	Office of Science Policy	https://osp.od.nih.gov/clinical-research/clinical-trials/
NIH	Division of AIDS (DAIDS) Site Clinical Operations and Research Essentials (SCORE) Manual: Premature Termination or Suspension of a Clinical Trial, 19 January 2021	https://www.niaid.nih.gov/sites/default/files/score-premature-termination-or-suspension-of-clinical-trial.pdf
NIH	https://grants.nih.gov/policy/clinical-trials/protocol-template.htm	https://grants.nih.gov/policy/clinical-trials/protocol-template.htm
NIH	Patient Recruitment Healthy Volunteer, NIH Clinical Center, 05/18/2022, Webpage accessed 2023-03-30	https://www.cc.nih.gov/recruit/volunteers.html
NIH	CTCAE	https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
NIST	Data Encryption Standard (DES)	https://csrc.nist.gov/publications/detail/fips/46/3/archive/1999-10-25
NIST	Guide to Protecting the Confidentiality of Personally Identifiable Information (PII)	https://csrc.nist.gov/publications/detail/sp/800-122/final
NIST	Minimum Security Requirements for Multi-user Operating Systems	https://csrc.nist.gov/csrc/media/publications/nistir/5153/final/documents/ir5153.txt
Office of the Privacy Commissioner of Canada	Privacy breaches	https://www.priv.gc.ca/en/privacy-topics/privacy-breaches/
OMB	Office of Management and Budget (OMB) Circular A-119	https://www.whitehouse.gov/wp-content/uploads/2017/11/Circular-119-1.pdf
PhUSE	PhUSE De-identification Standard for SDTM 3.2	http://www.phuse.eu/Data_Transparency_access.aspx
Publication	Russell Katz, Biomarkers and Surrogate Markers: An FDA Perspective, NeuroRx. 2004 Apr;1(2):189-95.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC534924/
S.H.Park, et al. In Situ Tissue Regeneration: Host Cell Recruitment and Biomaterial Design. Chapter 12. 2016	Chapter 12 - Functionalized Polymeric Biomaterials for In Situ Tissue Regeneration. S.H.Park, B.K.Lee, M.S.Kim. In Situ Tissue Regeneration, Host Cell Recruitment and Biomaterial Design. 2016, Pages 215-228	https://www.sciencedirect.com/science/article/pii/B978012802225200012X
SOCRA	SOCRA	https://www.socra.org/resources-and-faq/key-competencies/
Statistics in Medicine	Discussion in Peter B. Gilbert. SOME DESIGN ISSUES IN PHASE 2B VERSUS PHASE 3 PREVENTION TRIALS FOR TESTING EFFICACY OF PRODUCTS OR CONCEPTS. Stat Med. 2010 May 10; 29(10): 1061-1071.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929839/
StatPearls	Shreffler J, Huecker MR. Hypothesis Testing, P Values, Confidence Intervals, and Significance. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557421/	https://www.ncbi.nlm.nih.gov/books/NBK557421/
STROBE	www.strobe-statement.org	www.strobe-statement.org
Tetrascience	Tetrascience ALCOA++ principles for data integrity Fact Sheet	https://go.tetrascience.com/rs/152-SBL-014/images/Data-Integrity-Fact-Sheet.pdf
TransCelerate BioPharma Inc.	Clinical Data Transparency	http://www.transceleratebiopharmainc.com/assets/clinical-data-transparency/
UK MHRA	MHRA GXP Data Integrity Guidance and Defintions, Revision 1, March 2018	https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity
UK MHRA	MHRA GXP Data Integrity Guidance and Defintions, Revision 1, March 2018	https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity
US FDA	FDA 21 CFR Part 11	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11
US FDA	US FDA 21 CFR 50.20	https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/subpart-B/section-50.20
US FDA	US FDA (CDER) guidance, New Chemical Entity Exclusivity Determinations for Certain Fixed Combination Drug Products Guidance for Industry, October 2014	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-chemical-entity-exclusivity-determinations-certain-fixed-combination-drug-products
US FDA	US FDA. (04/08/2024). Novel Drug Approvals at FDA. Retrieved from URL https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda#:~:text=Certain%20drugs%20are%20classified%20as%20new%20molecular%20entities,products%20frequently%20provide%20important%20new%20therapies%20for%20patients.%20Webpage%20access%2020 24/04/18	https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda#:~:text=Certain%20drugs%20are%20classified%20as%20new%20molecular%20entities,products%20frequently%20provide%20important%20new%20therapies%20for%20patients.
US FDA	US FDA, Evaluation of Therapeutic Equivalence, Draft Guidance for Industry, July 2022	https://www.fda.gov/media/160054/download

US FDA	US FDA, Evaluation of Therapeutic Equivalence, Draft Guidance for Industry, July 2022	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence
US FDA	US FDA (CDER) guidance, New Chemical Entity Exclusivity Determinations for Certain Fixed Combination Drug Products Guidance for Industry, October 2014	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-chemical-entity-exclusivity-determinations-certain-fixed-combination-drug-products
US FDA	FDA Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, Final Rule Sept 2010	https://www.govinfo.gov/content/pkg/FR-2010-09-29/pdf/2010-24296.pdf
US Federal Government	FDAAA	https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-amendments-act-fdaaa-2007
USP	USP Nomenclature Guidelines (last revision on March 30, 2020)	https://www.usp.org/sites/default/files/usp/document/usp-nomenclature-guidelines.pdf
W3C	W3C Extensible Markup Language (XML)	https://www.w3.org/XML
WHO	International Programme on Chemical Safety (IPCS)	http://www.who.int/ipcs/about_ipcs/coordinator_report.pdf
WHO	Medical Devices	http://www.who.int/medical_devices/full_deffinition/en/
WHO	The World Health Organization Quality of Life (WHOQOL)	http://www.who.int/mental_health/publications/whoqol/en/
WHO	Basic Epidemiology, R. Bonita and others, WHO 2006	https://apps.who.int/iris/bitstream/handle/10665/43541/9241547073_eng.pdf;sequence=1
WHO	After World Health Organisation, Health products policy and standards, INN and medicines classification	https://www.who.int/teams/health-product-and-policy-standards/inn
WMA	Declaration of Helsinki	https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/